By Adria Calatayud
AstraZeneca reached a deal valued at up to $2.02 billion to license an experimental therapy for a disorder affecting cholesterol and related cardiovascular diseases from CSPC Pharmaceutical Group.
The U.K. pharmaceutical giant said Monday that CSPC will receive an upfront payment of $100 million and could receive up to $1.92 billion for further development and commercialization milestones plus royalties.
The agreement gives AstraZeneca access to a molecule discovered by CSPC, known as YS2302018, with the aim of developing it as a therapy with potential in a range of cardiovascular diseases, it said.
The molecule that AstraZeneca is licensing has been shown to prevent the formation of a protein that plays a key role in the transport of cholesterol in the blood stream, but has yet to be assessed in clinical trials.
The therapy candidate adds to AstraZeneca's cardiovascular pipeline and could help patients with dyslipidemia--a disorder affecting cholesterol--and related cardiometabolic diseases, said Sharon Barr, AstraZeneca executive vice president and head of bioPharmceuticals research and development.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 07, 2024 05:31 ET (09:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。